Baird Downgrades Regeneron Pharma (REGN) to Neutral; EPS Expectations Will Be Hard to Meet
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regeneron Pharma (REGN) PT Trimmed to $511 at Leerink Partners
August 5, 2016 8:03 AM EDTLeerink Partners analyst Geoffrey Porges trims its price target on Regeneron Pharma (NASDAQ: REGN) to $511.00 (from $530.00) but maintains an Outperform rating amid solid Q2 results.
Porges commented, "Regeneron announced solid 2Q16 results, with Eylea beating by 2% in the US and 5% overall; total... More
Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
August 4, 2016 2:55 PM EDTRoth Capital affirms Regeneron (Nasdaq: REGN) with a Buy rating and $520 price target following Q2 results and updated guidance, as reported... More
